Literature DB >> 23323143

Targeted therapies in medical oncology: successes, failures and next steps.

Gordon Mallarkey1, R Charles Coombes.   

Abstract

Year:  2013        PMID： 23323143      PMCID： PMC3539278          DOI： 10.1177/1758834012467829

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


× No keyword cloud information.
  3 in total

1.  Commentary on: "Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial." Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S, Escudier B. Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Joaquim Bellmunt, University Hospital del Mar-IMIM, Barcelona, Spain; Jill Clancy, Kongming Wang, Andreas G. Niethammer, Subramanian Hariharan, Pfizer, New York, NY; and Bernard Escudier, Institut Gustave Roussy, Villejuif, France.: J Clin Oncol. 2014 Mar 10;32(8):752-9; doi: 10.1200/JCO.2013.50.5305. [Epub 2013 Dec 2].

Authors:  Donald Trump
Journal:  Urol Oncol       Date:  2015-04-30       Impact factor: 3.498

2.  Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.

Authors:  Steven R Alberts; Daniel J Sargent; Suresh Nair; Michelle R Mahoney; Margaret Mooney; Stephen N Thibodeau; Thomas C Smyrk; Frank A Sinicrope; Emily Chan; Sharlene Gill; Morton S Kahlenberg; Anthony F Shields; James T Quesenberry; Thomas A Webb; Gist H Farr; Barbara A Pockaj; Axel Grothey; Richard M Goldberg
Journal:  JAMA       Date:  2012-04-04       Impact factor: 56.272

3.  Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Authors:  José Baselga; Ian Bradbury; Holger Eidtmann; Serena Di Cosimo; Evandro de Azambuja; Claudia Aura; Henry Gómez; Phuong Dinh; Karine Fauria; Veerle Van Dooren; Gursel Aktan; Aron Goldhirsch; Tsai-Wang Chang; Zsolt Horváth; Maria Coccia-Portugal; Julien Domont; Ling-Min Tseng; Georg Kunz; Joo Hyuk Sohn; Vladimir Semiglazov; Guillermo Lerzo; Marketa Palacova; Volodymyr Probachai; Lajos Pusztai; Michael Untch; Richard D Gelber; Martine Piccart-Gebhart
Journal:  Lancet       Date:  2012-01-17       Impact factor: 79.321
  3 in total
  4 in total

1.  CD317 Activates EGFR by Regulating Its Association with Lipid Rafts.

Authors:  Guizhong Zhang; Xin Li; Qian Chen; Junxin Li; Qingguo Ruan; Youhai H Chen; Xiaolu Yang; Xiaochun Wan
Journal:  Cancer Res       Date:  2019-03-19       Impact factor: 12.701

2.  Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue.

Authors:  Aleksandra Karolak; Katarzyna A Rejniak
Journal:  Bull Math Biol       Date:  2018-02-08       Impact factor: 1.758

3.  EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation.

Authors:  Hanane Lanaya; Anuradha Natarajan; Karin Komposch; Liang Li; Nicole Amberg; Lei Chen; Stefanie K Wculek; Martina Hammer; Rainer Zenz; Markus Peck-Radosavljevic; Wolfgang Sieghart; Michael Trauner; Hongyang Wang; Maria Sibilia
Journal:  Nat Cell Biol       Date:  2014-08-31       Impact factor: 28.824

Review 4.  Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma.

Authors:  Adarsh Vennepureddy; Nishitha Thumallapally; Vijeyaluxmy Motilal Nehru; Jean-Paul Atallah; Terenig Terjanian
Journal:  J Clin Med Res       Date:  2015-12-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.